Related Experiment Video
Updated: May 7, 2026

Ultrasonic Assessment of Myocardial Microstructure
Published on: January 14, 2014
Machine Learning-Based Discrimination of Cardiovascular Outcomes in Patients With Hypertrophic Cardiomyopathy
Tae-Min Rhee1,2, Yeon-Kyoung Ko3,4, Hyung-Kwan Kim1
1Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Insights
Machine learning models accurately predict major cardiovascular events in hypertrophic cardiomyopathy (HCM) patients. Left atrial diameter and hypertension are key predictors, improving risk stratification beyond traditional methods.
Area of Science:
- Cardiology
- Biomedical Engineering
- Data Science
Background:
- Traditional risk stratification for hypertrophic cardiomyopathy (HCM) has limitations.
- Novel approaches are needed to improve patient outcomes.
Purpose of the Study:
- To develop and validate machine learning (ML) models for predicting major adverse cardiovascular events (MACE) in HCM patients.
- To identify key clinical and echocardiographic features influencing cardiovascular risk in HCM.
Main Methods:
- Utilized data from 2,111 HCM patients, analyzing 25 clinical and echocardiographic features.
- Developed four ML models, selecting the best performing logistic regression model via cross-validation (AUROC).
- Employed SHapley Additive exPlanations (SHAP) to determine feature importance for MACE, all-cause death, heart failure admission, and stroke.
Main Results:
- The logistic regression model demonstrated strong predictive performance for MACE (AUROC=0.800) and its components.
- External validation confirmed the model's discriminant ability for MACE (AUROC=0.768), all-cause death (AUROC=0.750), and HF-adm (AUROC=0.806).
- SHAP analysis identified left atrial diameter and hypertension as significant predictors across all adverse outcomes.
Conclusions:
- ML models effectively discriminate cardiovascular events in HCM patients.
- The models provide valuable insights into key risk factors, enhancing current risk stratification strategies.
- Left atrial diameter and hypertension are crucial variables for predicting adverse outcomes in HCM.
Background:
Current risk stratification strategies for patients with hypertrophic cardiomyopathy (HCM) are limited to traditional methodologies.
Objectives:
The authors aimed to establish machine learning (ML)-based models to discriminate major cardiovascular events in patients with HCM.
Methods:
We enrolled consecutive HCM patients from 2 tertiary referral centers and used 25 clinical and echocardiographic features to discriminate major adverse cardiovascular events (MACE), including all-cause death, admission for heart failure (HF-adm), and stroke. The best model was selected for each outcome using the area under the receiver operating characteristic curve (AUROC) with 20-fold cross-validation. After testing in the external validation cohort, the relative importance of features in discriminating each outcome was determined using the SHapley Additive exPlanations (SHAP) method.
Results:
In total, 2,111 patients with HCM (age 61.4 ± 13.6 years; 67.6% men) were analyzed. During the median 4.0 years of follow-up, MACE occurred in 341 patients (16.2%). Among the 4 ML models, the logistic regression model achieved the best AUROC of 0.800 (95% CI: 0.760-0.841) for MACE, 0.789 (95% CI: 0.736-0.841) for all-cause death, 0.798 (95% CI: 0.736-0.860) for HF-adm, and 0.807 (95% CI: 0.754-0.859) for stroke. The discriminant ability of the logistic regression model remained excellent when applied to the external validation cohort for MACE (AUROC = 0.768), all-cause death (AUROC = 0.750), and HF-adm (AUROC = 0.806). The SHAP analysis identified left atrial diameter and hypertension as important variables for all outcomes of interest.
Conclusions:
The proposed ML models incorporating various phenotypes from patients with HCM accurately discriminated adverse cardiovascular events and provided variables with high importance for each outcome.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

